報價延遲最少15分鐘:2026/04/22 13:15 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.37 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.76/-2.44
|
|
企業價值
535.45M
|
| 資產負債 |
|
每股賬面淨值
1.99
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
170.44M
|
|
每股收益
1.88
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeuticproteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases. |
